EMA Clears Path for Novartis To Expand Market For SMA Gene Therapy Itvisma

 
• By Neena Brizmohun
  
Text, of SMA -Spinal Muscular Atrophy On Wooden blocks
Novartis's intrathecal formulation of its spinal muscular atrophy gene therapy could be approved in the EU soon (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from EU CHMP

More from Product Reviews